
    
The genomic variant c.1264G>T p.Val422Leu rs886042528 on the SCN1A gene is a missense mutation that has been associated with a severe neurological phenotype. This variant results in the substitution of valine to leucine at amino acid position 422. The SCN1A gene encodes the alpha subunit of the type 1 voltage-gated sodium channel (NaV1.1), which is critical for the initiation and propagation of action potentials in neurons. Mutations in SCN1A can lead to a variety of epilepsy syndromes, including Dravet syndrome, generalized epilepsy with febrile seizures plus (GEFS+), and other epileptic encephalopathies.The c.1264G>T p.Val422Leu variant has been specifically identified in a patient with early infantile SCN1A encephalopathy, a condition more severe than Dravet syndrome, characterized by profound developmental impairment and a prominent movement disorder with choreoathetosis, dystonia, and perioral hyperkinesia [6]. This phenotype is distinct from the typical seizure onset age range and intellectual disability seen in Dravet syndrome. The variant was described in a Japanese child presenting with infantile epileptic encephalopathy, hyperkinetic movement disorder, and hand stereotypies, indicating a severe impact on neurological function [6].Furthermore, the c.1264G>T variant has been reported in ClinVar with a total of four pathogenic submissions, supporting its association with disease. The conservation analysis and predictive functional assessments such as SIFT and Align-GVGD have indicated that this variant affects a highly conserved amino acid and is likely to impact the protein function [2]. The variant was classified as C15 by Align-GVGD, suggesting a high likelihood of being deleterious [2].In summary, the c.1264G>T p.Val422Leu rs886042528 variant in the SCN1A gene is a pathogenic mutation associated with severe neurological phenotypes, including early infantile SCN1A encephalopathy. The functional impact of this variant is supported by its conservation, predictive functional analyses, and clinical observations.

SCN1A遺伝子におけるゲノム変異c.1264G>T p.Val422Leu rs886042528は、重度の神経学的表現型と関連するミスセンス変異です。この変異は、アミノ酸位置422でバリン（Val）がロイシン（Leu）に置換される結果をもたらします。SCN1A遺伝子は、タイプ1電位依存性ナトリウムチャネル（NaV1.1）のαサブユニットをコードしており、ニューロンにおける活動電位の開始と伝播に重要な役割を果たします。SCN1Aの変異は、ドラベ症候群、発熱性けいれんを伴う全般てんかん（GEFS+）、その他のてんかん性脳症を含むさまざまなてんかん症候群を引き起こす可能性があります。

c.1264G>T p.Val422Leu変異は、ドラベ症候群よりも重度である早期乳児性SCN1A脳症の患者で特定されており、この疾患は深刻な発達障害と、舞踏アテトーゼ、ジストニア、口周囲の過運動を伴う顕著な運動障害を特徴としています[6]。この表現型は、ドラベ症候群で見られる典型的な発作発症年齢範囲や知的障害とは異なります。この変異は、乳児性てんかん性脳症、過運動性運動障害、手の常同行動を呈する日本人の子供で記述されており、神経機能に対する深刻な影響を示しています[6]。

さらに、c.1264G>T変異はClinVarで4件の病原性提出が報告されており、疾患との関連性を支持しています。保存性解析およびSIFTやAlign-GVGDなどの予測機能評価は、この変異が高度に保存されたアミノ酸に影響を与え、タンパク質機能に影響を及ぼす可能性が高いことを示しています[2]。この変異はAlign-GVGDでC15に分類されており、有害である可能性が高いことが示唆されています[2]。

まとめると、SCN1A遺伝子におけるc.1264G>T p.Val422Leu rs886042528変異は、早期乳児性SCN1A脳症を含む重度の神経学的表現型と関連する病原性変異です。この変異の機能的影響は、その保存性、予測機能解析、および臨床観察によって支持されています。
    
## References
- [1] Viswanathan LG et al. (2023). "Phenotypic features of epilepsy due to sodium channelopathies - A single center experience from India." Journal of neurosciences in rural practice, 14(4) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38059254/)
- [2] Kwong AK et al. (2012). "Identification of SCN1A and PCDH19 mutations in Chinese children with Dravet syndrome." PloS one, 7(7) [PubMed](https://pubmed.ncbi.nlm.nih.gov/22848613/)
- [3] SoRelle JA et al. (2020). "Assessment of Interlaboratory Variation in the Interpretation of Genomic Test Results in Patients With Epilepsy." JAMA network open, 3(4) [PubMed](https://pubmed.ncbi.nlm.nih.gov/32347949/)
- [4] Kwong AK et al. (2021). "High FGF-21 level in a cohort of 22 patients with Dravet Syndrome-Possible relationship with the disease outcomes." Epilepsia open, 6(4) [PubMed](https://pubmed.ncbi.nlm.nih.gov/34379890/)
- [5] Brunklaus A et al. (2022). "The gain of function SCN1A disorder spectrum: novel epilepsy phenotypes and therapeutic implications." Brain : a journal of neurology, 145(11) [PubMed](https://pubmed.ncbi.nlm.nih.gov/35696452/)
- [6] Sadleir LG et al. (2017). "Not all SCN1A epileptic encephalopathies are Dravet syndrome: Early profound Thr226Met phenotype." Neurology, 89(10) [PubMed](https://pubmed.ncbi.nlm.nih.gov/28794249/)
- [7] Butler KM et al. (2017). "Diagnostic Yield From 339 Epilepsy Patients Screened on a Clinical Gene Panel." Pediatric neurology, 77() [PubMed](https://pubmed.ncbi.nlm.nih.gov/29056246/)
- [8] Encinas AC et al. (2020). "Variable patterns of mutation density among NaV1.1, NaV1.2 and NaV1.6 point to channel-specific functional differences associated with childhood epilepsy." PloS one, 15(8) [SUPP] [PubMed](https://pubmed.ncbi.nlm.nih.gov/32845893/)

    
## ClinVar Submissions
- **[RCV000725185](https://www.ncbi.nlm.nih.gov/clinvar/RCV000725185/)**: not provided
- **[RCV001420525](https://www.ncbi.nlm.nih.gov/clinvar/RCV001420525/)**: Developmental and epileptic encephalopathy 6B
- **[RCV000314247](https://www.ncbi.nlm.nih.gov/clinvar/RCV000314247/)**: Severe myoclonic epilepsy in infancy
- **[RCV003955449](https://www.ncbi.nlm.nih.gov/clinvar/RCV003955449/)**: SCN1A-related condition

    